Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer

Man-Hsin Hung1,2, Kuen-Feng Chen3

  • 1a Division of Medical Oncology, Department of Oncology , Taipei Veterans General Hospital , Taipei , Taiwan.

Abstract

Insights

The SET protein drives cancer initiation, progression, and therapeutic resistance. Targeting SET and its interactions offers a promising anti-cancer strategy, though further research is needed for optimal clinical application.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • The SET protein is an oncoprotein implicated in cancer initiation and progression.
  • SET overexpression is tumor-specific and linked to poor clinical outcomes across various malignancies.
  • SET contributes to the development of therapeutic resistance in cancer cells.

Purpose of the Study:

  • To review the oncogenic roles, biological functions, and clinical relevance of SET protein in cancer.
  • To discuss the anti-cancer effects of preclinical SET antagonists.

Main Methods:

  • Literature review of existing evidence on SET protein in cancer.
  • Summary of preclinical investigations into SET antagonists.

Main Results:

  • SET plays a critical role in regulating diverse cancer hallmarks.
  • Emerging evidence highlights SET's involvement in therapeutic resistance.
  • Three SET antagonists show potential anti-cancer effects in preclinical studies.

Conclusions:

  • Targeting SET-associated protein interfaces is a potential anti-cancer strategy.
  • Further research is required to optimize combination therapies involving SET antagonists.
  • Identifying biomarkers for predicting responsiveness to SET-targeted treatments is crucial.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K